In this study, patients will receive a special cancer treatment vaccine called SurVaxM. This vaccine helps the immune system find and destroy cancer cells that have a protein called survivin. Survivin is found in many cancer cells but not in normal cells, making it a good target for treatment. The vaccine is mixed with an ingredient called Montanide ISA 51, which makes the immune response stronger, and a medicine called sargramostim that helps the vaccine work better.

The study has two parts: Priming and Maintenance. During Priming, patients get four shots over six weeks. If they do well, they move to Maintenance, receiving shots every eight weeks for up to two years. Doctors will watch for side effects for up to three years after the last treatment.

• Study Length: Up to three years of follow-up.
• Visits Needed: Shots every two weeks during initial phase, then every eight weeks.
• Eligibility: Patients aged 1-21 with certain brain tumors may qualify.

Participants should discuss the commitment and potential side effects with their doctors before joining.